- Previous Close
382.50 - Open
389.50 - Bid 383.50 x --
- Ask 388.00 x --
- Day's Range
382.00 - 389.50 - 52 Week Range
217.00 - 408.00 - Volume
9,468 - Avg. Volume
46,303 - Market Cap (intraday)
21.132B - Beta (5Y Monthly) 0.08
- PE Ratio (TTM)
31.11 - EPS (TTM)
12.47 - Earnings Date --
- Forward Dividend & Yield 11.00 (2.88%)
- Ex-Dividend Date Jul 17, 2024
- 1y Target Est
--
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax FACIALGAIN collagen implant with lidocaine, Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles; and Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes. It also provides Sunmax collagen dental bone graft, Sunmax collagen dental membrane, and Sunmax dental bone graft granules, which are used in the augmentation or reconstructive treatment of the alveolar ridge. In addition, the company offers Sunmax collagen bone graft matrix that provides a bone void filler that is resorbed and replaced with bone during the healing process; and skincare products comprising Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and Sunmax collagen skincare that are used as aftercare of dermal filler treatment. Sunmax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Tainan City, Taiwan.
www.sunmaxbiotech.comRecent News: 4728.TWO
View MorePerformance Overview: 4728.TWO
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4728.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4728.TWO
View MoreValuation Measures
Market Cap
20.83B
Enterprise Value
20.56B
Trailing P/E
30.70
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
21.98
Price/Book (mrq)
13.77
Enterprise Value/Revenue
21.66
Enterprise Value/EBITDA
22.56
Financial Highlights
Profitability and Income Statement
Profit Margin
37.37%
Return on Assets (ttm)
27.24%
Return on Equity (ttm)
46.24%
Revenue (ttm)
1.82B
Net Income Avi to Common (ttm)
679.4M
Diluted EPS (ttm)
12.47
Balance Sheet and Cash Flow
Total Cash (mrq)
865.47M
Total Debt/Equity (mrq)
9.60%
Levered Free Cash Flow (ttm)
400.4M